A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Ivacaftor (Primary) ; Lumacaftor (Primary) ; Moxifloxacin
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top